Communiqués Starpharma Holdings Limited

Actions

SPL

AU000000SPL0

Produits pharmaceutiques

Marché Fermé - Australian S.E. 08:10:10 25/09/2026			Varia. 5j.	Varia. 1 janv.
0,8400 ^AUD	+3,07%		+5,00%	+133,33%

26/08	Starpharma Holdings Limited publie ses résultats pour l'exercice clos le 30 juin 2026	CI
11/08	Starpharma Holdings lève 32 millions de dollars australiens via une offre de souscription intégralement garantie ; l'action chute de 16 %	MT

Communiqués

03/07	Starpharma : DEP milestone triggers partner option fee	PU
22/09/25	Starpharma Announces a Collaboration and License Agreement with Genentech	GL
22/03/23	Starpharma with Proactive at the ASX Small and Mid-Cap Conference	AQ
29/07/22	Starpharma : Quarterly Activities Report & Appendix 4C	PU
29/04/22	Starpharma : Quarterly Cashflow and Activities Report	PU
17/03/22	Starpharma : Application for quotation of securities - SPL	PU
20/02/22	Starpharma : Interim Report and Half-Year Financial Results	PU
01/02/22	Starpharma : Application for quotation of securities - SPL	PU
31/01/22	Starpharma - Quarterly Cashflow and Activities Report	AQ
28/01/22	Starpharma : Quarterly Cashflow and Activities Report	PU
21/01/22	Starpharma receives $7.7M R&D tax incentive refund	AQ
15/12/21	Starpharma - VIRALEZE antiviral nasal spray registered in Saudi Arabia	AQ
03/12/21	Starpharma : Notification regarding unquoted securities - SPL	PU
30/11/21	Starpharma : AGM Chairman address and CEO presentation	PU
09/11/21	Starpharma to present at Bell Potter Healthcare Conference	PU
30/03/21	Starpharma : VIRALEZE™ now launched by LloydsPharmacy in the UK	PU
25/03/21	Starpharma : VIRALEZE to be launched with Lloyds Pharmacy in the UK	AQ
24/03/21	Starpharma : VIRALEZE™ to be launched with LloydsPharmacy in the UK	PU
17/03/21	Starpharma : DEP HER2-lutetium outperforms in human breast cancer model	AQ
16/03/21	Starpharma : DEP® HER2-lutetium outperforms in human breast cancer model	PU
04/03/21	Starpharma : SPL7013 active against other pandemic coronaviruses	AQ
23/02/21	Starpharma : VIRALEZE antiviral nasal spray registered in Europe	AQ
22/02/21	Starpharma : VIRALEZE™ antiviral nasal spray registered in Europe	PU
12/02/21	Starpharma : signs DEP® ADC Research Agreement with MSD	PU
08/02/21	Starpharma : AZD0466 clinical DEP® program global expansion	PU